文献速递外周动脉疾病

ACEI/ARB改善慢性肢体威胁性缺血患者生存

Improved survival with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic limb-threatening ischemia.
PubMed 文献 · J Vasc Surg · 2020-04-08

基于Vascular Quality Initiative注册数据,纳入12433条肢体(11331例患者),经倾向评分匹配后分析显示,因慢性肢体威胁性缺血(CLTI)行外周血管介入(PVI)的患者中,使用ACEI/ARB与5年总生存(81.8% vs 79.9%;P=.01)和无截肢生存(73% vs 71.5%;P=.04)改善相关,但保肢率无差异(88.3% vs 88.1%;P=.56)。

要点

  • ACEI/ARB与CLTI患者PVI后5年总生存和无截肢生存改善独立相关。
  • ACEI/ARB未显著影响保肢率(88.3% vs 88.1%;P=.56)。
  • 需进一步研究ACEI/ARB在该人群中的使用,尤其有其他用药指征者。

核心结论

  • ACEI/ARB与CLTI患者PVI后总生存和无截肢生存改善独立相关,保肢率未受影响。

研究设计与样本

  • 回顾性队列研究,使用Vascular Quality Initiative注册数据,纳入2010年4月1日至2017年6月1日因CLTI行PVI的患者,共12433条肢体(11331例患者),采用倾向评分匹配控制基线差异。

主要发现

  • 匹配后5年总生存:ACEI/ARB组81.8% vs 无ACEI/ARB组79.9%(P=.01)。
  • 匹配后5年无截肢生存:ACEI/ARB组73% vs 无ACEI/ARB组71.5%(P=.04)。
  • 匹配后5年保肢率:ACEI/ARB组88.3% vs 无ACEI/ARB组88.1%(P=.56),无差异。
  • Cox回归多变量调整后,ACEI/ARB与总生存改善相关(HR 0.89;95%CI 0.80-0.99;P=.03)。
  • Cox回归多变量调整后,ACEI/ARB与无截肢生存改善相关(HR 0.92;95%CI 0.84-0.99;P=.04)。

关键数值与推荐

  • ACEI/ARB组冠状动脉疾病患病率31% vs 27%(P<.001),糖尿病67% vs 57%(P<.001),高血压94% vs 84%(P<.001),终末期肾病7% vs 12%(P<.001)。
  • 介入指征为组织丢失者:ACEI/ARB组64% vs 无ACEI/ARB组66%(P=.005)。

临床怎么用

  • 对因CLTI行PVI的患者,使用ACEI/ARB可能改善生存和无截肢生存,但需权衡个体适应证。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) reduce the risk of cardiovascular events in patients with peripheral artery disease. However, their effect on limb-specific outcomes is unclear. The objective of this study was to assess the effect of ACE inhibitors/ARBs on limb salvage (LS) and survival in patients undergoing peripheral vascular intervention (PVI) for chronic limb-threatening ischemia (CLTI). METHODS: The Vascular Quality Initiative registry was used to identify patients undergoing PVI for CLTI between April 1, 2010, and June 1, 2017. Patients with complete comorbidity, procedural, and follow-up limb and survival data were included. Propensity score matching was performed to control for baseline differences between the groups. LS, amputation-free survival (AFS), and overall survival (OS) were calculated in matched samples using Kaplan-Meier analysis. RESULTS: A total of 12,433 limbs (11,331 patients) were included. The ACE inhibitors/ARBs group of patients had significantly higher prevalence of coronary artery disease (31% vs 27%; P < .001), diabetes (67% vs 57%; P < .001), and hypertension (94% vs 84%; P < .001) and lower incidence of end-stage renal disease (7% vs 12%; P < .001). Indication for intervention was tissue loss in 64% of the ACE inhibitors/ARBs group vs 66% in the no ACE inhibitors/ARBs group (P = .005). Postmatching survival analysis at 5 years showed improved OS (81.8% vs 79.9%; P = .01) and AFS (73% vs 71.5%; P = .04) with ACE inhibitors/ARBs but no difference in LS (ACE inhibitors/ARBs, 88.3%; no ACE inhibitors/ARBs, 88.1%; P = .56). After adjustment for multiple variables in a Cox regression model, ACE inhibitors/ARBs were associated with improved OS (hazard ratio, 0.89; 95% confidence interval, 0.80-0.99; P = .03) and AFS (hazard ratio, 0.92; 95% confidence interval, 0.84-0.99; P = .04). CONCLUSIONS: ACE inhibitors/ARBs are independently associated with improved survival and AFS in patients undergoing PVI for CLTI. LS rates remained unaffected. Further research is required to investigate the use of ACE inhibitors/ARBs in this population of patients, especially CLTI patients with other indications for therapy with ACE inhibitors/ARBs.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Khan SZ, O'Brien-Irr MS, Rivero M, et al. Improved survival with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic limb-threatening ischemia. J Vasc Surg. 2020. PMID: 32276021. doi:10.1016/j.jvs.2020.02.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。